{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Transfusion+Dependent+Thalassemia&page=2",
    "query": {
      "condition": "Transfusion Dependent Thalassemia",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 41,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Transfusion+Dependent+Thalassemia&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Transfusion+Dependent+Thalassemia&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T03:09:06.692Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03432364",
      "title": "A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Transfusion Dependent Beta-thalassemia"
      ],
      "interventions": [
        {
          "name": "ST-400 Investigational product",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Sangamo Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 5,
      "start_date": "2018-03-29",
      "completion_date": "2022-11-17",
      "has_results": true,
      "last_update_posted_date": "2023-12-14",
      "last_synced_at": "2026-10-06T03:09:06.692Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Oakland, California • Atlanta, Georgia + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03432364"
    },
    {
      "nct_id": "NCT00176852",
      "title": "Stem Cell Transplant for Hemoglobinopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Thalassemia",
        "Severe Congenital Neutropenia",
        "Diamond-Blackfan Anemia",
        "Shwachman-Diamond Syndrome"
      ],
      "interventions": [
        {
          "name": "Busulfan, Fludarabine, ATG, TLI",
          "type": "DRUG"
        },
        {
          "name": "Busulfan, Cyclophosphamide, ATG, GCSF",
          "type": "DRUG"
        },
        {
          "name": "Campath, Fludarabine, Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Stem cell infusion",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "Up to 50 Years"
      },
      "enrollment_count": 22,
      "start_date": "2002-06",
      "completion_date": "2020-01",
      "has_results": true,
      "last_update_posted_date": "2020-02-27",
      "last_synced_at": "2026-10-06T03:09:06.692Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00176852"
    },
    {
      "nct_id": "NCT02633943",
      "title": "Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Transfusion-dependent Beta-Thalassemia"
      ],
      "interventions": [
        {
          "name": "Safety and efficacy assessments",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Genetix Biotherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "0 Years to 50 Years"
      },
      "enrollment_count": 66,
      "start_date": "2014-01",
      "completion_date": "2035-11",
      "has_results": false,
      "last_update_posted_date": "2025-04-09",
      "last_synced_at": "2026-10-06T03:09:06.692Z",
      "location_count": 6,
      "location_summary": "Oakland, California • Chicago, Illinois • Bethesda, Maryland + 3 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02633943"
    },
    {
      "nct_id": "NCT00873041",
      "title": "Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-transfusion Dependent Thalassemia"
      ],
      "interventions": [
        {
          "name": "deferasirox",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 166,
      "start_date": "2008-11",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2013-07-09",
      "last_synced_at": "2026-10-06T03:09:06.692Z",
      "location_count": 3,
      "location_summary": "Oakland, California • Chicago, Illinois • New York, New York",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00873041"
    },
    {
      "nct_id": "NCT03802201",
      "title": "Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "β-thalassemia",
        "Ineffective Erythropoiesis",
        "Chronic Anemia"
      ],
      "interventions": [
        {
          "name": "PTG-300",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Protagonist Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "12 Years to 65 Years"
      },
      "enrollment_count": 63,
      "start_date": "2018-12-19",
      "completion_date": "2020-07-31",
      "has_results": false,
      "last_update_posted_date": "2021-07-16",
      "last_synced_at": "2026-10-06T03:09:06.692Z",
      "location_count": 3,
      "location_summary": "Oakland, California • Boston, Massachusetts • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03802201"
    },
    {
      "nct_id": "NCT03653338",
      "title": "T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Anemia",
        "Beta-thalassemia Major",
        "Diamond-blackfan Anemia"
      ],
      "interventions": [
        {
          "name": "CD3/CD19 depleted leukocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CD45RA depleted leukocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Paul Szabolcs",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "5 Years to 40 Years"
      },
      "enrollment_count": 5,
      "start_date": "2018-08-02",
      "completion_date": "2028-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-10-06T03:09:06.692Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03653338"
    },
    {
      "nct_id": "NCT00872833",
      "title": "Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Thalassemia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Carelon Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2009-07",
      "completion_date": "2010-10",
      "has_results": true,
      "last_update_posted_date": "2015-10-07",
      "last_synced_at": "2026-10-06T03:09:06.692Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Oakland, California • Stanford, California + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00872833"
    },
    {
      "nct_id": "NCT04054921",
      "title": "Safety Study for Beta Thalassemia Subjects on PTG-300",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "β-thalassemia",
        "Ineffective Erythropoiesis"
      ],
      "interventions": [
        {
          "name": "PTG-300",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Protagonist Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "12 Years to 65 Years"
      },
      "enrollment_count": 34,
      "start_date": "2019-05-10",
      "completion_date": "2020-07-31",
      "has_results": false,
      "last_update_posted_date": "2021-07-16",
      "last_synced_at": "2026-10-06T03:09:06.692Z",
      "location_count": 2,
      "location_summary": "Oakland, California • Boston, Massachusetts",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04054921"
    },
    {
      "nct_id": "NCT03692052",
      "title": "A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thalassemia"
      ],
      "interventions": [
        {
          "name": "AG-348",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Agios Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2019-03-20",
      "completion_date": "2030-09-30",
      "has_results": true,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-10-06T03:09:06.692Z",
      "location_count": 2,
      "location_summary": "Oakland, California • Boston, Massachusetts",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03692052"
    },
    {
      "nct_id": "NCT06363760",
      "title": "A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Sickle Cell Disease",
        "Transfusion-dependent Beta-Thalassemia",
        "Hemoglobinopathies"
      ],
      "interventions": [
        {
          "name": "Safety and efficacy assessments",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Editas Medicine, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "12 Years to 50 Years"
      },
      "enrollment_count": 54,
      "start_date": "2024-06-17",
      "completion_date": "2040-08",
      "has_results": false,
      "last_update_posted_date": "2025-04-02",
      "last_synced_at": "2026-10-06T03:09:06.692Z",
      "location_count": 16,
      "location_summary": "Oakland, California • Aurora, Colorado • New Haven, Connecticut + 12 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06363760"
    }
  ]
}